|
United Therapeutics Wants Answers After FDA Denies Its PAH Drug
United Therapeutics (UT) is hoping to get some answers from an end-of-review meeting on why the FDA rejected its oral treprostinil diethanolamine extended-release tablets for pulmonary arterial hypertension (PAH).
This article is viewable by subscribers only. To view this article, please select an option below.
|
Subscribe
Archives